

Influence of time metrics on the treatment effect of intravenous alteplase prior to endovascular treatment in MR CLEAN-NO IV

Citation for published version (APA):

Rinkel, L. A., Treurniet, K. M., Kappelhof, M., LeCouffe, N. E., Bruggeman, A. A. E., Nieboer, D., van Zwam, W. H., Uyttenboogaart, M., Dippel, D. W. J., Emmer, B. J., Roos, Y. B. W. E. M., Majoie, C. B. L. M., Coutinho, J. M., & MR CLEAN-NO IV Investigators (2023). Influence of time metrics on the treatment effect of intravenous alteplase prior to endovascular treatment in MR CLEAN-NO IV. *Journal of Neurointerventional Surgery*, 15(E1), e54-e59. <https://doi.org/10.1136/jnis-2022-018998>

Document status and date:

Published: 01/01/2023

DOI:

[10.1136/jnis-2022-018998](https://doi.org/10.1136/jnis-2022-018998)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Influence of time metrics on the treatment effect of intravenous alteplase prior to endovascular treatment in MR CLEAN-NO IV

Leon A Rinkel ¹, Kilian Maurizio Treurniet ², Manon Kappelhof,²
Natalie E LeCouffe,¹ Agnetha A E Bruggeman ², Daan Nieboer,³
Wim H van Zwam ⁴, Maarten Uyttenboogaart ^{5,6}, Diederik W J Dippel ⁷,
Bart J Emmer,² Yvo B W E M Roos,¹ Charles B L M Majoie,² J M Coutinho ¹ on
behalf of the MR CLEAN-NO IV Investigators

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnis-2022-018998>).

For numbered affiliations see end of article.

Correspondence to

Dr J M Coutinho, Neurology, Amsterdam UMC Locatie AMC, Amsterdam 1105 AZ, Netherlands; j.coutinho@amsterdamumc.nl

Received 15 April 2022
Accepted 15 June 2022

ABSTRACT

Background We assessed whether the treatment effect of intravenous alteplase (IVT) prior to endovascular treatment (EVT) on functional outcome is modified by time metrics.

Methods We used data from all patients included in MR CLEAN-NO IV, a randomized trial of IVT followed by EVT versus EVT alone in patients who presented directly to EVT-capable hospitals. The primary outcome was the modified Rankin Scale score at 90 days. We used ordinal regression with a multiplicative interaction term to assess if the effect of IVT is modified by onset-to-randomization (OTR), onset-to-IV-needle (OTN), door-to-groin (DTG) or needle-to-groin (NTG) times. Secondary outcomes included successful reperfusion (extended Thrombolysis In Cerebral Infarction Scale 2b–3) and symptomatic intracranial hemorrhage (sICH).

Results In 539 included patients (266 allocated to IVT+EVT and 273 to EVT alone), median workflow times were OTR: 93 (IQR 71–145) min; OTN: 98 (IQR 75–156) min; DTG: 64 (IQR 51–78) min; and NTG: 28 (IQR 20–41) min. There was a significant association between worse outcomes and longer time intervals for all metrics except NTG. We found no interaction between any of the time metrics and IVT for the effect on functional outcome (p values for interaction: OTR=0.40, OTN=0.39, DTG=0.61, NTG=0.56). We also did not observe any significant interaction for successful reperfusion or sICH.

Conclusion In MR CLEAN-NO IV, the effect of IVT prior to EVT was not modified by OTR, OTN, DTG or NTG times. Our results do not support the use of these metrics to guide IVT treatment decisions prior to EVT in comprehensive stroke centres.

Trial registration number ISRCTN80619088.

INTRODUCTION

Rates of functional outcome after intravenous alteplase treatment (IVT) or endovascular treatment (EVT) for acute ischemic stroke are highly time dependent.^{1,2} Data of six randomized trials comparing EVT alone with IVT prior to EVT are currently available. The Chinese DIRECT-MT and DEVT trials showed non-inferiority of EVT alone,^{3,4} while non-inferiority was not demonstrated in MR

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Rates of functional outcome after intravenous alteplase treatment (IVT) or endovascular treatment (EVT) for acute ischemic stroke are highly time dependent, but there is a paucity of studies describing whether the effect of IVT prior to EVT is modified by time metrics.

WHAT THIS STUDY ADDS

⇒ We assessed whether the treatment effect of IVT prior to EVT on functional outcome is modified by onset-to-randomization (OTR), onset-to-IV-needle (OTN), door-to-groin (DTG) or needle-to-groin (NTG) times and found no interaction for any of these time metrics (p values for interaction: OTR=0.40, OTN=0.39, DTG=0.61, NTG=0.56).

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY

⇒ Our results suggest these time metrics should not be used to guide decisions on IVT prior to EVT in eligible patients presenting directly to comprehensive stroke centres. These findings should be confirmed using data from other randomized trials on IVT prior to EVT.

CLEAN-NO IV, DIRECT-SAFE, SKIP and SWIFT-DIRECT.^{5–9} Treatment-associated time metrics were differently distributed across these trials. Compared with DIRECT-MT and DEVT, MR CLEAN-NO IV reported relatively short onset-to-randomization (OTR), onset-to-needle (OTN) and door-to-groin (DTG) times while needle-to-groin (NTG) times were similar between the trials.^{3,4} The delay between symptom onset and administration of IVT, and between IVT and EVT, may influence the effectiveness of IVT and thus the treatment effect of IVT prior to EVT.^{10,11} This treatment effect may also be influenced by OTR and DTG times. We therefore aimed to assess whether OTR, OTN, DTG, and NTG times modify the effect of IVT prior to EVT on functional outcome.



© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Rinkel LA, Treurniet KM, Kappelhof M, et al. *J NeuroIntervent Surg* Epub ahead of print: [please include Day Month Year]. doi:10.1136/neurintsurg-2022-018998

Table 1 Baseline characteristics of the MR CLEAN-NO IV population

	MR CLEAN- NO IV population n=539
Allocated to IVT prior to EVT, n (%)§*	266 (49.4)
Median (IQR) age, years	71 (62–79)
Male sex, n (%)	305/539 (56.6)
Median (IQR) NIHSS score	16 (10–20)
Medical history, n (%)	
Previous ischemic stroke	91/539 (16.9)
Atrial fibrillation	58/539 (10.8)
Diabetes mellitus	90/539 (16.7)
Hypertension	260/538 (48.3)
Pre-stroke mRS score, n (%)	
0	374/538 (69.5)
1	100/538 (18.6)
2	49/538 (9.1)
≥3	15/538 (2.7)
Median (IQR) systolic blood pressure, mmHg	150 (133–169)
Median (IQR) glucose level, mmol/L ¶	6.7 (5.9–7.9)
Median (IQR) ASPECTS	9 (8–10)
Intracranial occlusion location, n (%)*	
Intracranial ICA	4/538 (0.7)
ICA-T	114/538 (21.2)
M1	330/538 (61.3)
Proximal M2	85/538 (15.8)
None	5/538 (0.9)
Tandem lesion, n (%)†	88/507 (17.4)
Collateral score, n (%)	
0	32/526 (6.1)
1	152/526 (28.9)
2	223/526 (42.4)
3	119/526 (22.6)
Adjuvant intra-arterial alteplase administered, n (%)‡	13 (2.4)
Median (IQR) duration, min	
From stroke onset to randomization	93 (71–145)
From door to randomization	27 (20–35)
From stroke onset to start of alteplase**	98 (75–156)
From door to start of alteplase**	31 (24–44)
From stroke onset to groin puncture††	133 (105–180)
From door to groin puncture††	64 (51–78)
From stroke onset to first reperfusion‡‡	174 (144–229)
From door to first reperfusion‡‡	102 (81–129)
From needle to groin§§	28 (20–41)

Missing data for ¶7, **15, ††40, ‡‡157, §§28 patients.
 *Five patients had an isolated occlusion of the extracranial ICA and thus were scored as having no intracranial occlusion. For one patient the occlusion location on CT angiography could not be assessed due to motion artifacts.
 †Tandem lesion is defined as an intracranial target occlusion with ipsilateral extracranial carotid dissection, significant atherosclerotic stenosis or atherosclerotic occlusion.
 ‡All 13 patients were allocated to the EVT alone group.
 §243/249 (98%) of patients who were treated with IVT prior to EVT received the full dose of IVT.
 ¶ASPECTS, Alberta Stroke Program Early CT Score; EVT, endovascular treatment; ICA, internal carotid artery; IVT, intravenous alteplase; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.

METHODS

Study design and patient selection

We used data from all patients included in MR CLEAN-NO IV, a multicenter randomized trial of IVT followed by EVT versus

EVT alone in patients with anterior circulation large vessel occlusion stroke who were eligible for both interventions and who presented directly to EVT-capable centers within 4.5 hours of stroke onset or last seen well.^{6 12} Patients were randomized to receive either IVT with alteplase (0.9 mg/kg) followed by EVT, or EVT alone without prior alteplase. IVT infusion was continued even if successful reperfusion was achieved during EVT prior to complete infusion. Rescue IVT (0.9 mg/kg) was permitted in patients allocated to EVT alone if there was incomplete reperfusion after EVT (score 0, 1, or 2A on the expanded Thrombolysis In Cerebral Infarction (eTICI) scale), and IVT could be administered within 4.5 hours of stroke onset. Adjuvant intra-arterial alteplase was permitted at the discretion of the interventionist. All relevant imaging was analysed by an imaging core laboratory, whose members were blinded to treatment allocation and all clinical data except for symptom side. An outcome committee, whose members were unaware of treatment

Table 2 Association of 30 min increase per time metric of interest with their effect on outcomes including interaction analyses with IVT treatment allocation

	Adjusted (common) OR (95% CI) per 30 min increase	P value for interaction with treatment allocation
Onset-to-randomization		
mRS shift	0.89 (0.83 to 0.95)	0.40
Functional independence*	0.89 (0.81 to 0.97)	0.13
Mortality†	1.17 (1.06 to 1.29)	0.95
Successful reperfusion‡	1.00 (0.90 to 1.11)	0.83
Symptomatic ICH§	1.23 (1.10 to 1.38)	0.53
Recanalization on first angiogram¶	1.01 (0.82 to 1.25)	0.83
Onset-to-needle		
mRS shift	0.88 (0.81 to 0.95)	0.39
Functional independence*	0.87 (0.79 to 0.97)	0.19
Mortality†	1.17 (1.05 to 1.30)	0.88
Successful reperfusion‡	1.00 (0.89 to 1.13)	0.97
Symptomatic ICH§	1.28 (1.10 to 1.49)	0.54
Recanalization on first angiogram¶	1.01 (0.82 to 1.26)	0.85
Door-to-groin		
mRS shift	0.76 (0.62 to 0.94)	0.61
Functional independence*	0.75 (0.57 to 0.99)	0.75
Mortality†	1.66 (1.22 to 2.26)	0.15
Successful reperfusion‡	0.64 (0.49 to 0.86)	0.98
Symptomatic ICH§	1.18 (0.73 to 1.90)	0.65
Recanalization on first angiogram¶	0.75 (0.39 to 1.44)	0.45
Needle-to-groin		
mRS shift	1.03 (0.79 to 1.34)	0.56
Functional independence*	0.98 (0.62 to 1.55)	0.63
Mortality†	1.17 (0.68 to 2.01)	0.58
Successful reperfusion‡	0.58 (0.37 to 0.91)	0.68
Symptomatic ICH§	1.03 (0.57 to 1.87)	0.94
Recanalization on first angiogram¶	0.76 (0.31 to 1.88)	0.95

Functional independence defined as mRS 0–2.
 Successful reperfusion defined as expanded Thrombolysis In Cerebral Infarction Scale 2b–3.
 Events occurred: *270/539 (50.1%), †98/539 (18.2%), ‡388/480 (80.8%), §30/539 (5.6%), ¶16/495 (3.2%).
 ICH, intracranial hemorrhage; mRS, modified Rankin Scale.

allocation, adjudicated functional outcome data. An adverse event committee evaluated the safety endpoints based on clinical data and reports from the imaging core laboratory.

Outcomes

The primary outcome was functional outcome measured with the modified Rankin Scale (mRS) score at 90 days after stroke (ranging from 0 (no disability) to 6 (death)). Secondary outcomes were mRS dichotomized at 0–2 (indicating functional independence) versus 3–6, mortality, successful reperfusion on the final intracranial angiogram (defined as an eTICI score of 2B, 2C, or 3), recanalization on first angiogram (defined as absence of treatable occlusion on first intracranial angiogram) and occurrence of symptomatic intracranial hemorrhage (sICH) according to the Heidelberg criteria.¹³

Statistical analysis

We assessed the association of the following time metrics with functional outcome: OTR, OTN, DTG and NTG times. We assessed whether the association between the time measures of interest and functional outcome was linear by determining if regression models with a restricted cubic spline transformation allowing three knots for time metrics improved model fit. For the primary outcome, we used ordinal logistic regression with multiplicative interaction terms between the time metrics of interest and treatment allocation to assess whether the association of IVT administration with functional outcome was modified. We assessed binary outcomes using logistic regression. We performed all main analyses in the intention to treat population. All regression analyses were adjusted for the variables pre-specified in the

MR CLEAN-NO IV statistical analysis plan¹² (age, pre-stroke mRS, OTR, National Institutes of Health Stroke Scale (NIHSS) score at baseline and collateral score), with the exception of analyses on OTR and OTN times for which we did not adjust for OTR. We additionally plotted the adjusted common OR of EVT alone for the time measures of interest. All time metrics were analysed as continuous variables and the effect of each time metric on outcomes was reported per 30 min increase. Missing data were imputed for the regression analyses only using multiple imputation methods.¹⁴ For regression analyses on OTN and NTG times, imputed data were used for patients in the EVT alone group since IVT-associated time metrics were unavailable due to treatment allocation. We performed an as-treated analysis in which we excluded all patients allocated to the EVT alone group who were treated with IVT as well as all patients allocated to IVT prior to EVT who did not receive full-dose IVT. All analyses were performed using R version 4.0.3 (R Foundation for Statistical Computing 2018, www.r-project.org).

RESULTS

Patient characteristics

Of 539 included patients, 266 (49.4%) were allocated to IVT prior to EVT and 273 (50.6%) to EVT alone (see online supplemental eFigure 1). Baseline characteristics of the trial population are shown in table 1. The median times for the intervals of interest were OTR: 93 (IQR 71–145) min; OTN: 98 (IQR 75–156) min; DTG: 64 (IQR 51–78) min, and NTG: 28 (IQR 20–41) min. All four time measures had a linear association with functional outcome (p value for non-linearity: OTR=0.39; OTN=0.50; DTG=0.63; NTG=0.30).




Figure 1 Adjusted common OR for a shift towards better functional outcome for endovascular treatment (EVT) alone versus intravenous alteplase (IVT) prior to EVT for onset-to-randomization (A), onset-to-needle (B), door-to-groin (C) and needle-to-groin times (D). Dashed lines represent 95% CIs.

Primary outcome

All time metrics were significantly associated with worse functional outcome, except NTG time (table 2). The adjusted common odds ratio (acOR) for functional outcome of EVT alone versus IVT followed by EVT in the trial population was 0.84 (95% CI 0.62 to 1.15). We found no interaction between any of the time metrics and IVT for the effect on functional outcome (p values for interaction: OTR=0.40, OTN=0.39, DTG=0.61, NTG=0.56). We plotted the acOR for functional outcome for EVT alone in relation to the time metrics of interest in figure 1.

Secondary outcomes

A longer DTG (adjusted OR (aOR) 0.64, 95% CI 0.49 to 0.86) and longer NTG (aOR 0.58, 95% CI 0.37 to 0.91) time was associated with lower rates of successful reperfusion after EVT (table 2). Increase in OTR (aOR 1.23, 95% CI 1.10 to 1.38) and in OTN (aOR 1.28, 95% CI 1.10 to 1.49) times were associated with higher rates of sICH. We observed no statistically significant interaction between the treatment effect of IVT prior to EVT and the studied time metrics for any of the secondary outcomes including mortality, successful reperfusion, and sICH.

Results of the as-treated analysis were largely similar to those of the main analysis (online supplemental eTable 2), but we did observe a statistically significant interaction between IVT treatment and OTR for functional independence (p=0.03). This corresponded with better outcomes for EVT alone in patients with longer OTR times (online supplemental eTable 3).

DISCUSSION

In MR CLEAN-NO IV, OTN, OTR and DTG had a significant association with worse functional outcome for every 30 min increase, while we did not find a significant association between NTG time and functional outcome. We observed no modification of the effect of IVT prior to EVT on functional outcome by these time metrics. We also did not find such effect modification for any of the secondary outcomes, including sICH and successful reperfusion.

The DIRECT MT, SKIP, and DEVT trials all reported no heterogeneity of treatment effect of IVT prior to EVT based on OTR times, but reported a non-significant trend that an increase in OTR favoured EVT alone.³⁻⁵ Only the DIRECT MT trial reported additional interaction analyses and assessed onset-to-groin, randomization-to-groin, onset-to-revascularization, and randomization-to-revascularization times, all of which showed no significant interaction.³

The effect of IVT for ischemic stroke is highly time dependent.¹¹⁻¹⁵ Functional outcomes are better for shorter OTN times.¹¹⁻¹⁶ In the current study we did not observe a significant interaction between treatment allocation of IVT prior to EVT and OTN despite this time dependency for IVT. As the effect of IVT prior to EVT on functional outcome appears to be modest,⁸ the sample size of our study may be too low to assess a difference in this effect based on the studied time metrics. A study performed prior to the widespread use of EVT suggested that cohorts including up to 900 patients yielded insufficient power to reliably assess the influence of OTN time on the effect of IVT,¹⁵ indicating that pooling of our results with other trials on EVT alone is important to confirm our findings.

The time interval for OTR was relatively short in our study, with 75% of patients presenting within 145 min after stroke onset, resulting in short OTN times. It may be that the treatment effect of IVT prior to EVT diminishes over time and that patients who present in later time windows benefit less from IVT prior

to EVT. This is what we observed for functional independence in the as-treated analysis, although this could have been a chance finding. As such, the interaction between OTR and IVT treatment should be assessed in further analyses which include more patients presenting in a later time window since symptom onset.

We observed no significant interaction between NTG time and IVT treatment allocation. We hypothesized that, when a very fast start of EVT is anticipated following IVT, this would favour EVT alone while longer intervals would favour IVT prior to EVT and that therefore NTG time would modify the effect of IVT. NTG times in our trial were relatively short, which could indicate that there was insufficient time for IVT to have an optimal effect prior to EVT. This is supported by the fact that only 8% of patients allocated to IVT prior to EVT had complete infusion of IVT before the start of EVT.⁶ The limited number of patients with longer NTG times in our study could explain why we did not observe such an interaction. It could also be argued that, in patients with short NTG time, IVT has more effect on distal emboli following revascularization with EVT and that we therefore did not observe an effect modification. All in all, we currently have no evidence for an interaction between IVT prior to EVT and NTG times based on both the findings of the current study and the fact that there were differences between the DIRECT MT, DEVT and MR CLEAN-NO IV trials in demonstrating non-inferiority while all reported similar NTG times.

This study has several limitations. First, this was a post-hoc analysis and not a prespecified analysis. Therefore, all results should be considered as exploratory only. Second, the generalizability of our results to other geographical areas with different distributions in time intervals is limited. Third, these results only apply to patients presenting directly to EVT-capable centers and not drip-and-ship patients.

CONCLUSION

In MR CLEAN-NO IV, the effect of IVT prior to EVT was not modified by OTR, OTN, DTG or NTG times. Our results do not support the use of these metrics to guide IVT decisions in eligible patients undergoing EVT in comprehensive stroke centers.

Author affiliations

¹Department of Neurology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands

²Department of Radiology and Nuclear Medicine, Amsterdam UMC Location AMC, Amsterdam, The Netherlands

³Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands

⁴Department of Radiology, Maastricht University Medical Center, Maastricht, The Netherlands

⁵Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands

⁶Department of Radiology and Nuclear Medicine, University Medical Center Groningen, Groningen, The Netherlands

⁷Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

Twitter Kilian Maurizio Treurniet @kiliantreurniet

Collaborators List of MR CLEAN-NO IV Investigators, Collaborators and Affiliations. Principal investigators: Yvo Roos,¹ Charles Majoie.¹ Study coordinators: Kilian Treurniet,¹ Jonathan Coutinho,¹ Bart Emmer,¹ Natalie LeCouffe,¹ Manon Kappelhof,¹ Leon Rinkel,¹ Agnetha Bruggeman.¹ Local principal investigators: Bob Roozenbeek,² Adriaan van Es,² Inger de Ridder,⁴ Wim van Zwam,⁴ Bart van der Worp,⁵ Rob Lo,⁵ Koos Keizer,⁶ Rob Gons,⁶ Lonneke Yo,⁶ Jelis Boiten,⁷ Ido van den Wijngaard,⁷ Geert Lycklama à Nijeholt,⁷ Jeanette Hofmeijer,⁸ Jasper Martens,⁸ Wouter Schonewille,⁹ Jan Albert Vos,⁹ Anil Tuladhar,¹⁰ Floris Schreuder,¹⁰ Jeroen Boogaarts,¹⁰ Sjoerd Jenniskens,¹⁰ Karlijn de Laat,¹¹ Lukas van Dijk,¹¹ Heleen den Hertog,¹² Boudewijn van Hasselt,¹² Paul Brouwers,¹³ Emiel Sturm,¹³ Tomas Bulut,¹³ Michel Remmers,¹⁴ Anouk van Norden,¹⁴ Thijs de Jong,¹⁴ Anouk Rozeman,¹⁵

Otto Elgersma,¹⁵ Maarten Uyttenboogaart,¹⁶ Reinoud Bokkers,¹⁶ Julia van Tuijl,¹⁷ Issam Boukrab,¹⁷ Hans Kortman,¹⁷ Vincent Costalat,¹⁸ Caroline Arquizan,¹⁸ Robin Lemmens,¹⁹ Jelle Demeestere,¹⁹ Philippe Desfontaines,²⁰ Denis Brisbois,²⁰ Frédéric Clarençon,²¹ Yves Samson.²¹ Local trial collaborators: Executive and writing committee Yvo Roos,¹ Charles Majoie,¹ Adriaan van Es,² Wim van Zwam,⁴ Jelis Boiten,⁷ Geert Lycklama à Nijeholt,⁷ Lonneke Yo,⁶ Koos Keizer,⁶ Jonathan Coutinho,¹ Bart Emmer,¹ Kilian Treurniet,¹ Natalie LeCouffe,¹ Manon Kappelhof.¹ Data Safety Monitoring Board: Martin Brown²² – Chair, Phil White,²³ John Gregson.²⁴ Independent trial statistician: Daan Nieboer.² CONTRAST clinical trial collaborators: Research leaders: Diederik Dippel,² Charles Majoie.¹ Consortium coordinator: Rick van Nuland.³ Imaging assessment committee: Charles Majoie¹ – Chair (Amsterdam Medical Center, location AMC); Aad van der Lugt² – Chair, Wim van Zwam,⁴ Linda Jacobi,⁴ René van den Berg,¹ Ludo Beenen,¹ Bart Emmer,¹ Adriaan van Es,² Pieter-Jan van Doormaal,² Geert Lycklama,⁷ Ido van den Wijngaard,⁷ Albert Yoo,²⁵ Lonneke Yo,⁶ Jasper Martens,⁸ Bas Hammer,¹¹ Stefan Roosendaal,² Anton Meijer,¹⁰ Menno Krietemeijer,⁶ Reinoud Bokkers,¹⁶ Anouk van der Hoorn,¹⁶ Dick Gerrits.¹³ Adverse event committee: Robert van Oostenbrugge⁴ – Chair, Bart Emmer,² Jonathan Coutinho,¹ Ben Jansen.¹⁷ Outcome assessment committee: Yvo Roos¹ – Chair, Sanne Manschot,⁷ Diederik Dippel,² Henk Kerkhof,¹⁵ Ido van den Wijngaard,⁷ Jonathan Coutinho,¹ Peter Koudstaal,¹ Koos Keizer.⁶ Data management group: Hester Lingsma,² Diederik Dippel,² Vicky Chalos,² Olvert Berkhemer.² Imaging data management: Aad van der Lugt,² Charles Majoie,¹ Adriaan Versteeg,² Lennard Wolff,² Jiahang Su,² Manon Tolhuisen,¹ Henk van Voorst.¹ Biomaterials and translational group: Hugo ten Cate,⁴ Moniek de Maat,² Samantha Donse-Donkel,² Heleen van Beusekom,² Aladdin Taha.² Local collaborators: Vicky Chalos,² Kilian Treurniet,¹ Sophie van den Berg,¹ Natalie LeCouffe,¹ Rob van de Graaf,² Robert-Jan Goldhoorn,⁴ Aladdin Taha,² Samantha Donse-Donkel,² Wouter Hinsenvelde,⁴ Anne Pison,⁴ Lotte Sondag,¹⁰ Manon Kappelhof,¹ Rik Reinink,⁵ Manon Tolhuisen,¹ Josje Brouwer,¹ Lennard Wolff,² Sabine Collette,¹⁶ Wouter van der Steen,² Research nurses: Rita Sprengers,¹ Martin Sterrenberg,² Naziha El Ghannouti,² Sabrina Verheesen,⁴ Wilma Pellikaan,⁹ Kitty Blauwendraat,⁹ Yvonne Drabbe,¹¹ Joke de Meris,⁷ Michelle Simons,⁸ Hester Bongenaar,⁶ Anja van Loon,¹⁴ Eva Ponjee,¹² Rieke Eilander,¹² Suze Kooij,¹⁵ Marieke de Jong,¹⁶ Esther Santeagoes,¹⁷ Suze Roodenburg,¹⁵ Ayla van Ahee,¹⁵ Marinette Moynier,¹⁸ Annemie Devroye,¹⁹ Evelyn Marcis,¹⁹ Ingrid Iezzi,²⁰ Annie David,²⁰ Atika Talbi.²¹ Study monitors: Leontien Heiligers,² Yvonne Martens.² Affiliations: ¹Amsterdam University Medical Centers, location AMC, University of Amsterdam, Amsterdam the Netherlands; ²Erasmus MC University Medical Center, Rotterdam, the Netherlands; ³Lygature, Utrecht, the Netherlands; ⁴Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, the Netherlands; ⁵University Medical Center Utrecht, Brain Center Rudolf Magnus, Utrecht, the Netherlands; ⁶Catharina Hospital, Eindhoven, the Netherlands; ⁷Haaglanden Medical Center, the Hague, the Netherlands; ⁸Rijnstate Hospital, Arnhem, the Netherlands; ⁹St Antonius Hospital, Nieuwegein, the Netherlands; ¹⁰Radboud University Medical Center, Nijmegen, the Netherlands; ¹¹HagaZiekenhuis, the Hague, the Netherlands; ¹²Isala Klinieken, Zwolle, the Netherlands; ¹³Medisch Spectrum Twente, Enschede, the Netherlands; ¹⁴Amphia Hospital, Breda, the Netherlands; ¹⁵Albert Schweitzer Hospital, Dordrecht, the Netherlands; ¹⁶University Medical Center Groningen, the Netherlands; ¹⁷Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands; ¹⁸Centre Hospitalier Universitaire de Montpellier, Montpellier, France; ¹⁹Universitair Ziekenhuis Leuven, Leuven, Belgium; ²⁰Centre Hospitalier Chrétien, Liège, Belgium; ²¹Pitié-Salpêtrière Hospital, Paris, France; ²²National Hospital for Neurology and Neurosurgery, London, UK; ²³Institute of Neuroscience and Newcastle University Institute for Ageing, Newcastle University, Newcastle, UK; ²⁴London School of Hygiene & Tropical Medicine, London, UK; ²⁵Texas Stroke Institute, Plano, Texas, USA.

Contributors All authors contributed to the design of the work and the acquisition, analysis, or interpretation of data. LAR drafted the manuscript, all other authors made critical revisions and substantial contributions and approved the final manuscript. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the manuscript are appropriately investigated and resolved. Guarantors: LAR and JMC.

Funding The MR CLEAN-NO IV trial was funded through the CONTRAST consortium, which acknowledges the support from the Netherlands Cardiovascular Research Initiative, an initiative of the Dutch Heart Foundation (CVON2015-01: CONTRAST), and from the Brain Foundation Netherlands (HA2015.01.06). The collaboration project is additionally financed by the Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public-private partnerships (LSHM17016). This work was funded in part through unrestricted funding by Stryker, Medtronic and Cerenovus. The funding sources were not involved in study design, monitoring, data collection, statistical analyses, interpretation of results, or manuscript writing.

Competing interests WHVZ reports speaker fees from Cerenovus, Stryker European Operations BV and NicoLab, paid to institution. DWJD reports grants for research from the Dutch Heart Foundation, Brain Foundation Netherlands, The Netherlands Organization for Health Research and Development, Health Holland Top Sector Life Sciences & Health, and unrestricted grants from Penumbra, Stryker European Operations BV, Medtronic, Thrombolytic Science and Cerenovus, all paid to institution. YBWEEMR is a minor shareholder of NicoLab. JMC received unrelated research support from The Netherlands Organisation for Health Research and Development, Dr C J Vaillant Foundation, Bayer, Boehringer, Portola. All fees were paid to his employer. CBLMM reports grants from TWIN Foundation, related to MR CLEAN Registry, paid to institution, and unrelated grants from CVON/Dutch Heart Foundation, European Commission, Dutch Health Evaluation Program, Stryker (all paid to institution), shareholder NicoLab. BJE reports grants from Health Holland Top Sector Life Sciences & Health as well as from the Leading the Change Program (The Netherlands Organization for Health Research and Development), both paid to institution. NLC reports an honorarium for a short presentation at the American Academy of Neurology 2022. The other authors report no conflicts.

Patient consent for publication Not applicable.

Ethics approval The trial protocol for the MR CLEAN-NO IV trial was approved by Dutch (MEC-2017–368), Belgian (ID-RCB: 2018-A00764-51), and French (B322201939935, 19/20/987) ethical committees and the research board of each participating center. Patients or their representatives provided written informed deferred consent.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs

Leon A Rinkel <http://orcid.org/0000-0002-0291-8515>
 Kilian Maurizio Treurniet <http://orcid.org/0000-0003-3227-3620>
 Agnetha A E Bruggeman <http://orcid.org/0000-0002-6873-2545>
 Wim H van Zwam <http://orcid.org/0000-0003-1631-7056>
 Maarten Uyttenboogaart <http://orcid.org/0000-0002-6934-4456>
 Diederik W J Dippel <http://orcid.org/0000-0002-9234-3515>
 J M Coutinho <http://orcid.org/0000-0002-8284-982X>

REFERENCES

- 1 Fransen PSS, Berkhemer OA, Lingsma HF, *et al*. Time to reperfusion and treatment effect for acute ischemic stroke: a randomized clinical trial. *JAMA Neurol* 2016;73:190.
- 2 Gumbinger C, Reuter B, Stock C, *et al*. Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials. *BMJ* 2014;348:g3429.
- 3 Yang P, Zhang Y, Zhang L, *et al*. Endovascular thrombectomy with or without intravenous alteplase in acute stroke. *N Engl J Med* 2020;382:1981–93.
- 4 Zi W, Qiu Z, Li F, *et al*. Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke: the DEVT randomized clinical trial. *JAMA* 2021;325:234–43.
- 5 Suzuki K, Matsumaru Y, Takeuchi M, *et al*. Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke: the SKIP randomized clinical trial. *JAMA* 2021;325:244–53.
- 6 LeCouffe NE, Kappelhof M, Treurniet KM, *et al*. A randomized trial of intravenous alteplase before endovascular treatment for stroke. *N Engl J Med* 2021;385:1833–44.
- 7 Fischer U, Kaesmacher J, Strbian D, *et al*. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. *Lancet* 2022;400:104–15.
- 8 Podlasek A, Dhillon PS, Butt W, *et al*. Direct mechanical thrombectomy without intravenous thrombolysis versus bridging therapy for acute ischemic stroke: a meta-analysis of randomized controlled trials. *Int J Stroke* 2021;16:621–31.
- 9 Mitchell PJ, Yan B, Churilov L, *et al*. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 H of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial. *Lancet* 2022;400:116–25.
- 10 Zhu F, Gauberti M, Marnat G, *et al*. Time from i.v. thrombolysis to thrombectomy and outcome in acute ischemic stroke. *Ann Neurol* 2021;89:511–9.

- 11 Lees KR, Bluhmki E, von Kummer R, *et al.* Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. *Lancet* 2010;375:1695–703.
- 12 Treurniet KM, LeCouffe NE, Kappelhof M, *et al.* MR CLEAN-NO IV: intravenous treatment followed by endovascular treatment versus direct endovascular treatment for acute ischemic stroke caused by a proximal intracranial occlusion- study protocol for a randomized clinical trial. *Trials* 2021;22:141.
- 13 von Kummer R, Broderick JP, Campbell BCV, *et al.* The Heidelberg bleeding classification. *Stroke* 2015;46:2981–6.
- 14 van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. 2011. *J Statistical Software* 2011;45:1–67. doi:10.18637/jss.v045.i03
- 15 Saver JL, Fonarow GC, Smith EE, *et al.* Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. *JAMA* 2013;309:2480.
- 16 Berge E, Whiteley W, Audebert H, *et al.* European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. *Eur Stroke J* 2021;6:I–LXII.